Autolus Therapeutics (AUTL) News Today → 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad) Free AUTL Stock Alerts $4.39 +0.32 (+7.86%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 7:06 AM | finance.yahoo.comQ1 2024 Autolus Therapeutics PLC Earnings CallMay 17 at 3:37 PM | investorplace.comAUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024May 17 at 3:37 PM | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $9.00 price target on shares of Autolus Therapeutics in a report on Friday.May 17 at 12:32 PM | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.07Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.07May 17 at 11:00 AM | finance.yahoo.comAutolus Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesMay 17 at 7:00 AM | globenewswire.comAutolus Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesMay 16 at 4:00 PM | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Trading 4.1% Higher Autolus Therapeutics (NASDAQ:AUTL) Shares Up 4.1%May 16 at 12:58 PM | markets.businessinsider.comHere's what to expect from Autolus Therapeutics's earnings reportMay 14, 2024 | seekingalpha.comAutolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An OpportunityMay 14, 2024 | marketbeat.comShort Interest in Autolus Therapeutics plc (NASDAQ:AUTL) Decreases By 13.5%Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) saw a large decline in short interest in April. As of April 30th, there was short interest totalling 3,520,000 shares, a decline of 13.5% from the April 15th total of 4,070,000 shares. Based on an average daily trading volume, of 1,880,000 shares, the days-to-cover ratio is presently 1.9 days.May 14, 2024 | globenewswire.comAutolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) CongressMay 13, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Trading Down 3.5%Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 3.5%May 13, 2024 | finance.yahoo.comAutolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference CallMay 1, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Sees Unusually-High Trading VolumeAutolus Therapeutics (NASDAQ:AUTL) Sees Large Volume IncreaseApril 27, 2024 | wsj.comAutolus Therapeutics Ltd. ADRApril 25, 2024 | finance.yahoo.comRecent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 yearApril 24, 2024 | globenewswire.comAbstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCOApril 23, 2024 | globenewswire.comAutolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024April 21, 2024 | nasdaq.comRSI Alert: Autolus Therapeutics (AUTL) Now OversoldApril 19, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Shares Down 5.2% Autolus Therapeutics (NASDAQ:AUTL) Trading Down 5.2%April 18, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Trading 3.7% Higher Autolus Therapeutics (NASDAQ:AUTL) Shares Up 3.7%April 12, 2024 | markets.businessinsider.comBuy Rating on Autolus Therapeutics: Innovative Cancer Treatments and Strategic Leadership Drive Positive OutlookApril 12, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Stock Rating Reaffirmed by Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $9.00 price target on shares of Autolus Therapeutics in a report on Friday.April 11, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Trading Up 3.3%Autolus Therapeutics (NASDAQ:AUTL) Shares Up 3.3%April 9, 2024 | investing.comTruist raises Autolus Therapeutics stock target on market lead potentialApril 9, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Given New $11.00 Price Target at Truist FinancialTruist Financial lifted their price objective on Autolus Therapeutics from $10.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday.April 8, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Stock Price Down 3.6%Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 3.6%April 4, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Trading Up 4.9%Autolus Therapeutics (NASDAQ:AUTL) Shares Up 4.9%April 2, 2024 | finance.yahoo.comAutolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)April 1, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Trading Down 7.5%Autolus Therapeutics (NASDAQ:AUTL) Trading Down 7.5%April 1, 2024 | globenewswire.comAutolus Therapeutics Announces Changes to its Board of DirectorsMarch 31, 2024 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Short Interest Up 13.7% in MarchAutolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 3,150,000 shares, a growth of 13.7% from the February 29th total of 2,770,000 shares. Based on an average daily volume of 1,680,000 shares, the days-to-cover ratio is currently 1.9 days.March 25, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday TradingMarch 25, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $6.32Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $6.32March 21, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Trading Down 4.6%Autolus Therapeutics (NASDAQ:AUTL) Trading Down 4.6%March 20, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Trading 4.5% Higher Autolus Therapeutics (NASDAQ:AUTL) Shares Up 4.5%March 18, 2024 | marketbeat.comAutolus Therapeutics' (AUTL) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $9.00 price objective on shares of Autolus Therapeutics in a report on Thursday.March 18, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Price Target Increased to $10.00 by Analysts at Truist FinancialTruist Financial lifted their price objective on Autolus Therapeutics from $9.00 to $10.00 and gave the company a "buy" rating in a research report on Monday.March 18, 2024 | markets.businessinsider.comBreaking Down Autolus Therapeutics: 4 Analysts Share Their ViewsMarch 17, 2024 | finance.yahoo.comAutolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call TranscriptMarch 16, 2024 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Sees Significant Decline in Short InterestAutolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) saw a large decline in short interest in February. As of February 29th, there was short interest totalling 2,770,000 shares, a decline of 10.6% from the February 14th total of 3,100,000 shares. Based on an average daily trading volume, of 1,650,000 shares, the days-to-cover ratio is presently 1.7 days.March 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Autolus Therapeutics Amid Strong Progress and Potential of Obe-celMarch 15, 2024 | finance.yahoo.comQ4 2023 Autolus Therapeutics PLC Earnings CallMarch 15, 2024 | finance.yahoo.comAutolus Therapeutics Full Year 2023 Earnings: EPS Misses ExpectationsMarch 15, 2024 | finanznachrichten.deAutolus Therapeutics plc: Autolus Therapeutics Reports Full Year 2023 Financial Results and Business UpdatesMarch 15, 2024 | msn.comAutolus Therapeutics FY 2023 Earnings PreviewMarch 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL)March 14, 2024 | finance.yahoo.comAutolus Therapeutics PLC Reports Full Year 2023 Financial ResultsMarch 14, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Shares Up 11.5%Autolus Therapeutics (NASDAQ:AUTL) Trading Up 11.5%March 14, 2024 | seekingalpha.comAutolus Therapeutics plc 2023 Q4 - Results - Earnings Call Presentation Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. AUTL Media Mentions By Week AUTL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AUTL News Sentiment▼0.670.51▲Average Medical News Sentiment AUTL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AUTL Articles This Week▼153▲AUTL Articles Average Week Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BioCryst Pharmaceuticals News Today Scholar Rock News Today Mesoblast News Today Immatics News Today Relay Therapeutics News Today Cullinan Oncology News Today REGENXBIO News Today Vir Biotechnology News Today CARGO Therapeutics News Today 4D Molecular Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AUTL) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaObama’s Forever Term [exposed]Porter & CompanyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryMost important medical advance in 100 yearsThe Oxford ClubBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
